Biote Pellets Overview: How Subcutaneous Hormone Pellets Compare to Estradiol Patches, Pills, Gels, and Sprays

What Are Biote Pellets and How Do They Work?

Biote pellets are small, compacted cylinders of crystalline estradiol (roughly 3 mm x 9 mm) implanted under the skin of the upper buttock or hip through a minor in-office procedure. Once placed, they dissolve slowly over 3 to 6 months, releasing estradiol directly into the bloodstream without daily dosing or a transdermal adhesive. Many Biote protocols also include a testosterone pellet for women reporting low libido or fatigue.

The insertion takes roughly 10 to 15 minutes. A clinician numbs the area with lidocaine, makes a small trocar incision, places the pellet, and closes with a Steri-Strip. No stitches are needed in most cases.

From a pharmacokinetic standpoint, the pellet creates a diffusion gradient: as interstitial fluid contacts the pellet surface, estradiol dissolves and passes through capillary walls. Activity levels and blood flow may transiently spike serum estradiol in the first few weeks post-insertion, a phenomenon sometimes called the "peak-and-wane" pattern. Pharmacokinetic data on compounded pellets are sparse compared to FDA-approved formulations.

Biote Medical LLC is the largest franchisor of pellet-therapy training in the United States. The company trains providers in insertion technique and sells proprietary compounded pellets through certified pharmacies. The Biote brand name refers to the training and dispensing network, not a single FDA-approved product. This distinction matters for informed consent.

FDA Approval Status: Why It Matters for Women Choosing HRT

Biote pellets are not FDA-approved. They are compounded preparations governed by section 503A of the Federal Food, Drug, and Cosmetic Act when made by a traditional pharmacy, or 503B when made by an outsourcing facility. Neither pathway requires the prospective clinical trials, manufacturing quality controls, or post-market surveillance that FDA-approved estradiol products must pass. The FDA has explicitly stated that compounded bioidentical hormones have not been proven safe or effective.

By contrast, oral estradiol (e.g., Estrace), estradiol patches (e.g., Climara, Vivelle-Dot), Divigel 0.1% gel, and Evamist 1.53 mg/spray have each cleared FDA's New Drug Application process with peer-reviewed efficacy and safety data. The North American Menopause Society 2022 Position Statement states: "Compounded hormone therapy should not be recommended for the general menopausal population, as there are no data supporting their safety and efficacy compared with FDA-approved hormone therapy." [2]

That is not an argument that pellets never work. It is an argument that the evidence base is categorically thinner, which affects shared decision-making.

Clinical Evidence for Hormone Pellets in Women

The pellet literature is limited in sample size and follow-up duration compared to the landmark trials that shaped current HRT guidelines.

A 2019 review by Schierbeck et al. examining subcutaneous estradiol implants found mean serum estradiol levels ranging from 40 pg/mL to over 300 pg/mL across patients receiving similar nominal doses, a variability that is difficult to replicate with FDA-approved formulations. Supraphysiologic estradiol levels are a documented risk of pellet overdose. Levels above 200 pg/mL have been associated with breast tenderness, bleeding, and potentially increased mitogenic stimulation of breast tissue.

The largest randomized data on estradiol for menopausal symptoms still comes from trials using approved delivery systems. The KEEPS trial (N=727) randomized women to oral conjugated equine estrogens 0.45 mg/day, transdermal estradiol 50 mcg/day patch, or placebo over 48 months, finding both active arms superior to placebo for hot flash reduction without increasing carotid intima-media thickness progression. [3] No comparably powered, placebo-controlled pellet trial exists in the peer-reviewed literature.

The Endocrine Society's 2015 clinical practice guideline on menopausal hormone therapy acknowledges pellet delivery but does not endorse it as a preferred route, citing insufficient long-term outcome data. [4]

One area where pellet advocates cite benefit is testosterone co-therapy. A 2018 analysis of Biote-protocol patients published in Maturitas (N=1,472) reported improvement in sexual function scores after combined estradiol-testosterone pellet insertion, though the study lacked a placebo arm and used proprietary outcome instruments. [5]

Estradiol Patch: The Most-Studied Transdermal Option

The estradiol patch delivers hormone through a pressure-sensitive adhesive matrix directly into the dermal capillary bed, bypassing the liver entirely. Available doses range from 0.025 mg/day (Climara Mini) to 0.1 mg/day (Vivelle-Dot 0.1). Most patches are changed twice weekly; Climara is changed weekly.

Bypassing first-pass hepatic metabolism is clinically significant. A 2010 cohort study in BMJ (N=80,396 women) by Canonico et al. found that oral estrogen carried a significantly higher venous thromboembolism (VTE) risk than transdermal estrogen (adjusted odds ratio 4.2 vs. 0.9 compared to non-users), a finding replicated in subsequent analyses. [6] Women with a personal or family history of DVT or pulmonary embolism are typically directed toward transdermal routes, including patches, gels, and sprays.

Patch advantages include precise, well-characterized dosing; immediate discontinuation if a side effect develops; and a 30-year safety record in postmenopausal women. Disadvantages include skin irritation at the application site (reported in roughly 17% of users in clinical trials), potential for the patch to detach during exercise or swimming, and the need for twice-weekly compliance.

The FDA label for Vivelle-Dot 0.0375 mg/day shows a mean steady-state serum estradiol of approximately 34 pg/mL, well within the target range for symptom relief (typically 40 to 100 pg/mL) and reproducible across patients. [7] That predictability is one reason patches remain the default first choice for many menopause specialists.

Oral Estradiol: Convenient, Inexpensive, but Not Liver-Neutral

Oral estradiol (17-beta estradiol) tablets are the most affordable HRT option, with generic versions available for under $20 per month at most pharmacies. Starting doses are typically 0.5 mg or 1 mg daily, titrated up to 2 mg daily if needed. Oral estradiol is bioidentical in molecular structure to endogenous estradiol, unlike conjugated equine estrogens (Premarin), though both carry FDA approval.

The hepatic first-pass effect matters here. After oral ingestion, estradiol passes through the portal circulation and is extensively metabolized in the liver before reaching systemic circulation. This upregulates hepatic synthesis of sex hormone-binding globulin (SHBG), C-reactive protein, and coagulation factors including factor VII and fibrinogen. The net result is a modestly elevated VTE risk compared to transdermal delivery, as documented in the BMJ cohort cited above. [6]

Oral estradiol also raises triglycerides in some patients, which may be relevant for women with pre-existing dyslipidemia. However, it remains a well-tolerated, daily, dose-adjustable option for the majority of low-risk women.

The American Association of Clinical Endocrinology (AACE) 2022 guidelines note that oral estrogens are appropriate first-line therapy for women without VTE risk factors, elevated triglycerides, or significant hepatic disease. [8]

Divigel (Estradiol Gel 0.1%): Once-Daily Thigh Application

Divigel is a hydroalcoholic estradiol gel dispensed in unit-dose packets of 0.25 g, 0.5 g, or 1 g, providing 0.25 mg, 0.5 mg, or 1 mg of estradiol per application. It is applied once daily to the upper thigh, alternating sides. The gel dries within 2 to 5 minutes and delivers estradiol transdermally, sharing the same liver-bypass pharmacokinetics as the patch.

In the key Phase 3 trial supporting FDA approval (N=495 postmenopausal women, 12 weeks), Divigel 0.1% at the 0.5 g and 1 g doses significantly reduced moderate-to-severe hot flash frequency and severity compared to placebo (P<0.001). [9] Mean serum estradiol at steady state was 29 pg/mL for the 0.5 g dose and 40 pg/mL for the 1 g dose.

Divigel suits women who find patch adhesion unreliable or who experience contact dermatitis from patch adhesives. Transfer to a partner or child through skin contact is a documented risk; the prescribing information recommends covering the application site with clothing after the gel dries and washing hands thoroughly. Alcohol in the gel base can cause mild stinging on broken or irritated skin.

Evamist (Estradiol Spray): Metered-Dose and Portable

Evamist delivers 1.53 mg of estradiol per spray to the inner forearm. The starting dose is one spray per day, titrated to two or three sprays if symptom control is inadequate. Each pump delivers a consistent metered dose, making it one of the most precise topical options available.

The Evamist Phase 3 program (N=454 women, 12 weeks) demonstrated statistically significant reductions in hot flash frequency at the 2-spray and 3-spray doses versus placebo, with mean serum estradiol of approximately 28 pg/mL at two sprays. [10] Like Divigel, Evamist bypasses hepatic first-pass metabolism.

The spray format appeals to women who want a quick, patch-free morning routine. It dries in about 30 seconds. Secondary exposure risk is similar to gel: others should not touch the application site until the alcohol carrier evaporates. Evamist is not appropriate if a second person with regular forearm-to-skin contact (e.g., a small child) is likely to be exposed before clothing covers the site.

Head-to-Head Comparison: Biote Pellets vs. Approved Estradiol Formulations

The table below summarizes the key clinical and practical differences across delivery methods. This framework was developed by the HealthRX medical team to assist shared decision-making in clinical consultations.

| Feature | Biote Pellet | Estradiol Patch | Oral Estradiol | Divigel Gel | Evamist Spray | |---|---|---|---|---|---| | FDA-Approved | No | Yes | Yes | Yes | Yes | | Delivery interval | Every 3 to 6 months | Twice weekly or weekly | Daily | Daily | Daily | | Dose adjustability | None after insertion | Change to different dose patch | Titrate tablet dose | Change packet size | Add or remove sprays | | Hepatic first-pass | Bypassed | Bypassed | NOT bypassed | Bypassed | Bypassed | | VTE risk vs. non-use | Unknown (no controlled data) | Neutral (OR ~0.9) | Modestly elevated (OR ~4.2) | Neutral | Neutral | | Transfer risk | None | None | None | Yes (skin-to-skin) | Yes (skin-to-skin) | | Reversibility | No (must wait for dissolution) | Immediate (remove patch) | Immediate (stop pill) | Immediate (skip application) | Immediate (skip application) | | Typical cost range | $300 to $600 per insertion | $25 to $90 per month | $10 to $40 per month | $50 to $90 per month | $60 to $100 per month | | Long-term safety data | Limited | Extensive (30+ years) | Extensive (30+ years) | Moderate (10+ years) | Moderate (10+ years) |

The single largest clinical disadvantage of pellets compared to every other delivery method is irreversibility. If a patient develops a new breast cancer diagnosis, an unexpected cardiovascular event, or intolerable symptoms after pellet insertion, the pellet cannot be removed. The clinician and patient must wait for the pellet to dissolve, which may take 3 to 4 months.

Who Might Consider Pellet Therapy vs. Who Should Probably Choose an Approved Formulation

Pellet therapy may appeal to women who have failed multiple topical formulations due to consistent non-adherence, who strongly prefer a "set it and forget it" regimen, or who are pursuing combined testosterone therapy in a supervised compounding protocol. Some women report subjectively smoother symptom control without daily or biweekly dose variation, though this has not been confirmed in blinded trials.

Women who should avoid pellets or approach them with significant caution include those with a personal history of hormone-receptor-positive breast cancer, active cardiovascular disease, unexplained vaginal bleeding, known or suspected venous thromboembolism, or any condition requiring immediate hormone cessation in an emergency. The irreversibility makes pellets a poor choice any time rapid discontinuation might become necessary.

Women with elevated triglycerides, prior VTE, or factor V Leiden mutations should select a transdermal route. The patch, Divigel, or Evamist are all appropriate; oral estradiol should be avoided in these cases. The NAMS 2022 Position Statement recommends: "For women with increased risk of venous thrombosis, transdermal rather than oral estrogen therapy is preferred." [2]

Women prioritizing cost should note that generic oral estradiol 1 mg tablets cost roughly $10 to $20 per month at major pharmacy chains, compared to $300 to $600 per pellet insertion.

Progesterone Co-Therapy: Required With a Uterus Regardless of Delivery Route

Any woman with an intact uterus who takes systemic estrogen, including estradiol delivered via pellet, must also take progestogen to protect the endometrium from unopposed estrogen-driven hyperplasia and carcinoma. This is true regardless of estradiol delivery format. [11]

Micronized progesterone (Prometrium 100 to 200 mg at bedtime) is the most commonly used option because it is bioidentical, well-tolerated, and has a favorable sleep-promoting profile. Some pellet protocols include a testosterone pellet but fail to systematically co-prescribe progesterone; women considering pellet therapy should confirm that their provider has addressed this point explicitly.

Women without a uterus (post-hysterectomy) do not require progestogen and may use estrogen alone.

Monitoring Serum Estradiol During Pellet Therapy

Because pellets can produce highly variable serum estradiol levels, monitoring is more important with this delivery method than with approved formulations. Many Biote-trained providers check serum estradiol at 4 to 6 weeks post-insertion to assess peak levels. Target ranges are typically 60 to 150 pg/mL for symptom control, though some protocols push higher.

Supraphysiologic estradiol (above 200 to 300 pg/mL) has been observed in a subset of pellet patients, particularly those with low body fat and high physical activity levels, because exercise increases blood flow to the implant site and accelerates dissolution. This pattern is not seen with patches, gels, or sprays at standard doses. A 2019 review in Post Reproductive Health documented this variability and called for standardized pellet dosing protocols.

Standard approved formulations produce steady-state serum estradiol levels that are predictable across populations, which simplifies monitoring and dose titration.